Matinas Biopharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone to the Martinez Biopharma First Quarter 2024 Financial Results Conference Call. Currently, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by the number one on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference is being recorded. I would now like to turn the conference over to Jody Cain. Please go ahead. This is Jody Cain with LHA Investor Relations. Thank you for participating in today's call. Joining me from Martinez Biopharma are Jerry Jabbour, Chief Executive Officer, and Keith Cassenti, Chief Financial Officer. Dr. Terry Makovits, Chief Development Officer, and Dr. Terry Ferguson, Chief Medical Officer, will be available during the question and answer session. I'd like to remind listeners that remarks made during this call may state management's future intentions, hopes, beliefs, expectations, or projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements are made pursuant to the safe harbor provisions of federal securities laws. These forward-looking statements are based on Matinas Biopharma's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Matinus Biopharma files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on sec.gov...